Biotin

證據等級: L5

預測適應症: 2 個

Biotin: From Nutritional Supplement to Dyspepsia

One-Sentence Summary

Biotin (Vitamin B7) is an essential micronutrient acting as a coenzyme for multiple carboxylases, traditionally used as a nutritional supplement without a registered drug indication in India’s market. The TxGNN model predicts it may be effective for Dyspepsia, however, current evidence support is limited — with 0 directly relevant clinical trials and only 1 marginally related publication — placing this candidate at evidence level L4.

Quick Overview

Item	Content
Original Indication	Nutritional supplement (Vitamin B7); no registered drug indication on record
Predicted New Indication	Dyspepsia
TxGNN Prediction Score	99.43%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Biotin (Vitamin B7) serves as an essential cofactor for multiple carboxylase enzymes — including acetyl-CoA carboxylase, pyruvate carboxylase, and propionyl-CoA carboxylase — playing a central role in fatty acid synthesis, gluconeogenesis, and amino acid metabolism. Biotin deficiency is known to manifest with gastrointestinal symptoms such as nausea and vomiting, suggesting an indirect relationship between Biotin status and digestive tract function.

A second line of reasoning links Biotin to gut health through the gut microbiome: intestinal bacteria can both produce and consume Biotin, and Biotin may modulate intestinal epithelial barrier integrity. Functional dyspepsia is increasingly understood as a disorder with multifactorial pathogenesis, including microbiome dysbiosis and impaired mucosal barrier function. The theoretical chain connecting Biotin repletion to symptomatic relief in dyspepsia is therefore mechanistically plausible — but remains at the level of hypothesis.

Importantly, no direct mechanistic evidence or controlled clinical data currently establish Biotin as an active therapeutic agent for dyspepsia. The TxGNN model’s graph-based prediction may reflect shared network proximity between Biotin’s metabolic nodes and gastrointestinal disease pathways, rather than a direct causal pharmacological link. This prediction should be interpreted as a hypothesis-generating signal, not a validated therapeutic claim.

Clinical Trial Evidence

Both trials retrieved from ClinicalTrials.gov were assessed as Grade C (false-positive retrieval, no direct relevance):

Trial Number	Phase	Status	Enrollment	Assessment
NCT05389813	Phase 2/3	Unknown	150	Irrelevant — Compares Oxycodone vs Pregabalin for postoperative pain control; no connection to Biotin or dyspepsia
NCT03360435	N/A	Completed	99	Indirectly related at best — Examines transdermal vitamin absorption (including Biotin) in post-bariatric surgery patients; dyspepsia is not an endpoint; population-specific findings are not generalizable

Note: No clinical trials directly investigating Biotin for dyspepsia treatment were identified.

Literature Evidence

Of 7 publications retrieved, only 1 has meaningful (though indirect) relevance to Biotin in dyspepsia. The remainder concern IBS pathophysiology, H. pylori gastritis, or unrelated conditions where Biotin appears incidentally.

PMID	Year	Type	Journal	Key Findings
25384804	2014	Clinical Interventional Study	Minerva Gastroenterol Dietol	Open multicentric study evaluating a multi-ingredient supplement (sodium alginate, calcium carbonate, pineapple, papaya, ginger, α-galactosidase, fennel — product name “Bioten”) in functional dyspepsia post-H. pylori treatment; Biotin itself is not an independent variable
15863846	2005	Case Report	J Dermatology	Infant with Biotin deficiency initially diagnosed as having dyspepsia and fed amino acid formula; Biotin deficiency caused dermatological manifestations — dyspepsia was the presenting context, not the outcome
21695955	2011	Clinical Study	Exp Clin Gastroenterology	Evaluates a prebiotic supplement (Stimbifid) containing inulin, oligofructose, and multiple vitamins including Biotin in patients with bronchopulmonary disease on antibiotics; GI microbiota correction was assessed, dyspepsia not a primary endpoint
25110039	2014	Observational	Int J Mol Med	Describes antral endocrine cell changes in IBS patients vs healthy controls; no Biotin involvement
24891930	2014	Observational	World J Gastrointest Endoscopy	Examines oxyntic mucosa endocrine cells in IBS; no Biotin involvement
11304845	2001	Histological/Immunological Study	J Clin Pathol	IL-10 localisation in H. pylori-associated gastritis; no Biotin involvement
10354275	1999	Basic/Histological Study	Kidney International	Small bowel mucosal findings in IgA nephropathy; unrelated to Biotin or dyspepsia

Summary: No published RCT or controlled study directly tests Biotin as a treatment for dyspepsia. The most relevant paper (PMID 25384804) evaluates a compound supplement where Biotin is not an isolable variable.

India Market Information

Biotin is not registered as a pharmaceutical product in India’s drug regulatory database. No marketing authorisations were identified.

Biotin may be commercially available in India as a food supplement, nutraceutical, or over-the-counter vitamin product, but this falls outside the scope of the drug repurposing regulatory framework evaluated here.

Safety Considerations

Please refer to the package insert for safety information.

No drug-drug interaction data were identified in the DDI database query. No formal key warnings or contraindications data were retrieved from the regulatory source. Given Biotin’s status as an essential micronutrient with a well-established safety profile at physiological doses, the absence of formal safety filings reflects its classification as a nutritional supplement rather than a high-risk pharmaceutical.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a high prediction score (99.43%) for Biotin in dyspepsia, but this score does not correspond to clinical evidence — both retrieved clinical trials are false-positive matches, and no controlled study has specifically tested Biotin as a therapeutic agent for dyspepsia. The mechanistic rationale is theoretically coherent (cofactor role in gut metabolism, microbiome interactions, epithelial barrier modulation) but remains unvalidated. With evidence level L4 and no India market presence, this candidate is not ready for clinical translation.

To proceed, the following would be needed:

Mechanistic validation: Preclinical studies (in vitro / animal models) directly testing Biotin supplementation in dyspepsia models, including functional dyspepsia and gastroparesis
Human pilot data: A prospective observational or open-label pilot study assessing Biotin status and GI symptom correlation in dyspepsia patients
Dose-response clarification: Distinction between physiological supplementation doses (µg/day) and pharmacological doses (e.g., high-dose MD1003 used in neurological research), since the therapeutic hypothesis may require supratherapeutic dosing
Regulatory pathway assessment: Determine whether the relevant submission would proceed under a drug or functional food/nutraceutical regulatory framework in India
Safety package: Formal retrieval of package insert warnings and contraindications data from a regulatory source, particularly if high-dose Biotin is being evaluated (high-dose Biotin is known to interfere with immunoassay-based laboratory tests, a clinically significant concern)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.